COMMUNIQUÉS West-GlobeNewswire

Heartflow, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
11/08/2025
MOUNTAIN VIEW, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), a leader in AI technology for coronary artery disease (CAD), today announced the closing of its upsized initial public [...]
Anteris Announces Results for the Second Quarter of 2025
11/08/2025
MINNEAPOLIS and BRISBANE, Australia, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ( Anteris or the Company ) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, [...]
Quipt Home Medical Reports Improved Fiscal Third Quarter 2025 Results
11/08/2025
Posts Positive Organic Growth and Adjusted EBITDA ‎ 1 of 23.5% of Revenue CINCINNATI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (“ Quipt ” or the “ Company ”) (NASDAQ: QIPT; TSX: QIPT), a U.S. based [...]
Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement
12/08/2025
TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“ Revive ” or the “ Company ”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative [...]
REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion
11/08/2025
Treatment of a subgroup of patients with post-acute sequelae of SARS-CoV-2. Forecast adds to Tevogen Bio's Oncology therapeutic area projections of $1 billion in the launch year and $10–$14 billion over the first five [...]
Booking Health Unveils New Study: Role of Immunotherapy in Extending Life Expectancy for Stage4 Cervical Cancer Patients
11/08/2025
Langenfeld, Germany, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Booking Health , a global leader in medical treatment coordination, today unveiled a new study titled Role of Immunotherapy in Extending Life Expectancy for Stage 4 [...]
Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion
11/08/2025
WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN ), reiterates investor confidence and estimated asset value over $10 billion. In October 2024, HMP [...]
Inventiva Participera à la « Canaccord Genuity 45th Annual Growth Conference »
11/08/2025
Daix (France), New York City (New York, Etats-Unis), le 11 aout 2025 – Inventiva (Euronext Paris et Nasdaq : IVA ) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de [...]
Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference
11/08/2025
Daix (France), New York City (New York, United States), August 11, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development [...]
NTG Nordic Transport Group publishes interim report for H1 2025
11/08/2025
Company announcement no. 9 – 25 11 August 2025 NTG Nordic Transport Group publishes interim report for H1 2025 The interim report for H1 2025 is enclosed. In connection with publication of the results for H1 2025, a [...]
TOMI Environmental Solutions, Inc. to Hold Conference Call to Discuss Second Quarter 2025 Financial Results on August 14, 2025
11/08/2025
FREDERICK, Md., Aug. 11, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced it will report [...]
Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow
11/08/2025
Total eligible patients in the US exceed 2 million. Treatment of SARS-CoV-2 infection in solid and hematologic cancer patients under active treatment. Reflects business philosophy of commercial success through patient [...]
BHIANT Quarterly Update: North Texas Bio Innovation Gains Momentum with Workforce Development and Industry Collaboration
11/08/2025
DALLAS, Aug. 11, 2025 (GLOBE NEWSWIRE) -- BHIANT , the workforce development arm of BioNTX, is charting new ground in biotechnology talent development and industry collaboration, strengthening North Texas’ position as a [...]
Esteworld Opens First UK Representative Office in London’s Covent Garden
11/08/2025
Photo: Esteworld Opens Its First Representative Office in the UK in London LONDON, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Turkish aesthetic healthcare group Esteworld has strengthened its presence in the UK market with the [...]
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results
11/08/2025
Positive 16-week data from APEX Phase 2 Part A met all primary and key secondary endpoints for APG777, a potentially best-in-class anti-IL-13 antibody, in moderate-to-severe atopic dermatitis APEX Part A testing every 3 [...]
Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update
11/08/2025
Reported positive KT-621 (STAT6) Phase 1 healthy volunteer data surpassing Kymera’s target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in moderate to severe [...]
Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
11/08/2025
– Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment period – – Dravet syndrome is a rare genetic disease characterized by refractory seizures and [...]
GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2
11/08/2025
The first patient in Cohort 3, the fifth patient in the trial, has completed the first week of cycle 1 following the successful safety review of Cohort 2 with no safety or tolerability issues observed The company plans [...]
FoRx Therapeutics Initiates First-in-Human Trial with Novel Anti-Cancer Drug FORX-428 Targeting DNA Damage Response
11/08/2025
Novel PARG inhibitor FORX-428 has shown best-in-class characteristics in preclinical studies Trial initially taking place in the U.S., following IND clearance Initial data expected in mid-2026 from open-label Phase 1 [...]

Pages